A massive £200k has been pledged to IiME (Invest In ME) by a charitable foundation towards the UK Rituximab treatment trial which will replicate the work pioneered by Norwegian researchers. This research involving the cancer drug Rituximab gives clues to the pathophysiology of the disease and may also produce bio-markers that may be used in future to help diagnosis. Rituximab acts on B cells and so the positive effects on a large proportion ME/CFS patients suggests that at least a subgroup have a disease with an autoimmune element. The researchers are just as interested in those who aren’t helped by Rituximab as those who are, so this research may be beneficial for all ME/CFS patients.
http://www.investinme.org/IIME%20Statement%20UKRT%202013-09-24.htm